One-year Effectiveness and Side Effects of Fingolimod in Multiple Sclerosis Patients

Authors

  • Ahmadi, Poona Neurologist ,Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
  • Fakhri, Negin MSc in Biostatistics, Student Research Committee, Faculty of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran
  • Razazian, Nazanin Professor, Department of Neurology, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
  • Rezaei, Mansour Professor, Department of Biostatistics, Social Development and Health Promotion Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
Abstract:

 Background and purpose: Fingolimod, is one of the first oral disease-modifying treatments (DMT) that has shown efficacy in advanced clinical trials for the treatment of multiple sclerosis (MS). The present study examined the one-year effectiveness and side effects of fingolimod. Materials and methods: In this quasi-experimental study, 26 MS patients attending Kermanshah Imam Reza Hospital were treated with fingolimod for one year (2018-19). Before and after treatment, the severity of disability (EDSS score), frequency of active lesions on MRI, and incidence of drug-related complications were studied. Data were analyzed using SPSS V25. Results: The mean age of patients was 34.23 ± 6.9 (17-44 years old), including 20 (76.9%) females and 6 (23.1%) males. The average duration of disease was 7.63±4.7 years. Relapsing-remitting multiple sclerosis (RRMS) and relapsing progressive (PRMS) were observed in 23 (88.5%) and 3 (11.5%) patients, respectively. The EDSS score was significantly lower at the end of the study (2.29±2.0) than the beginning of the study (3.12±1.9) (P= 0.001). The frequency of cases with active lesions in MRI was 63.6% before the treatment that decreased to 40.0% after treatment (P>0.05). No immediate side effects were reported, but delayed complications occurred in 27% of RRMS patients, including hair loss (n=1), increased liver enzyme levels (n=3), cardiac complications (n=2), and depression (n=1). PRMS patients had no delayed complications. Conclusion: Fingolimod has a good effect in RRMS and PRMS patients with tolerable side effects.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Evaluation of the one-year effectiveness and side effects of rituximab in patients with multiple sclerosis in Kermanshah

Background: Multiple sclerosis (MS) is an inflammatory disease affecting the central nervous system. Rituximab (Zytux) is a type of monoclonal antibody against B cells with CD20 antigen that reduces B cells. The present study examined the one-year effectiveness and side effects of Rituximab. Methods: This quasi-experimental clinical trial was conducted from September 2018 to September 2019 in ...

full text

Evaluating the efficacy and side effects fingolimod in 3 -year follow-up of patients in RRMS

Fingolimod is the first DMT drug to treat MS that oral form was available. This study was done with aim to study the effectiveness and long-term side effects of bio similar fingolimod oral forms in 3-year follow-up of patients with RRMS.     Methods: This study was a clinical trial (before and after) on 28 patients with RRMS referring to Clinic of Imam Reza Hospital in Kermanshah. Patients r...

full text

Comparing the Quality of Life in Patients With Multiple Sclerosis Consuming Fingolimod and CinnoVex

Background: Multiple Sclerosis (MS) is a chronic demyelinating, inflammatory, and degenerative disease of the central nervous system. MS gradually limits and deteriorates the patients’ quality of life. Objectives: This study aimed to evaluate and compare the quality of life in patients with MS consuming Fingolimod and CinnoVex. Materials & Methods: In an analytical cross-sectional study, 106 ...

full text

Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis

Introduction: Fingolimod is the first confirmed oral immune-modulator to treat Relapsing-Remitting Multiple Sclerosis (RRMS). This study aimed to investigate the safety and efficacy of fingolimod therapy in Iranian patients with RRMS. Methods: In our trial, 50 patients resistant to conventional interferon therapy were assigned to receive fingolimod 0.5 mg per day for 12 months. The number of D...

full text

Fingolimod and multiple sclerosis

Neurology 2012;79:1942–1943 Unexpected consequences arise from our incomplete knowledge of the immune system. Who, for example, would have predicted that natalizumab, a monoclonal antibody targeting 4 integrin on leukocytes, would dramatically increase the risk of developing progressive multifocal leukoencephalopathy without causing notable immunosuppression? Thus, any new immunomodulatory ther...

full text

Side Effects of First and Second Doses of Inactivated COVID-19 Vaccine in Multiple Sclerosis

Background: It is currently recommended to vaccinate against SARS CoV-2 for people with multiple sclerosis (MS), but it is uncertain what effect it will have on people with MS (PwMS). Objectives: We aimed to compare the side effects of the first and second doses of the Sinopharm vaccine in PwMS. Materials & Methods: This descriptive-analytical follow-up study was conducted on PwMS patients...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 31  issue 203

pages  173- 179

publication date 2021-12

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

No Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023